Key points are not available for this paper at this time.
This analysis confirms the IDFS benefit from adding pertuzumab to standard adjuvant therapy for patients with node-positive HER2-positive early BC. Longer follow-up is needed to fully assess OS benefit.
Piccart et al. (Thu,) studied this question.